title: Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effects.
abstract: Carcinoid tumors and endocrine pancreatic tumors often express somatostatin receptors (sst). Tumor spread may be visualized by sst scintigraphy using [(111)In-DTPA-D-Phe1]-octreotide. In this study, tumor targeting therapy with [(111)In-DTPA-D-Phe1]-octreotide at high doses (6 GBq every third week) was used to treat patients with sst-expressing tumors. Five patients entered the protocol and three were evaluable for response, while all could be evaluated for toxicity. Two patient responded with a significant reduction in tumor markers (> 50%). The third patient showed increasing levels of tumor markers. Side effects were expressed as depression of bone-marrow function. In one patient a grade 4 reduction in platelet count was observed requiring several thrombocyte transfusions. In another two patients platelet counts decreased significantly. We conclude that treatment with [(111)In-DTPA-D-Phe1]-octreotide can be used in patients with neuroendocrine tumors but blood parameters have to be carefully monitored to avoid severe side effects.
authors.affiliation: Department of Medical Sciences, University Hospital, Uppsala, Sweden. Eva.TiensuuvJanson@medicin.uu.se
authors.forename: E
authors.initials: E
authors.lastname: Tiensuu Janson
authors.forename: B
authors.initials: B
authors.lastname: Eriksson
authors.forename: K
authors.initials: K
authors.lastname: Oberg
authors.forename: B
authors.initials: B
authors.lastname: Skogseid
authors.forename: U
authors.initials: U
authors.lastname: Ohrvall
authors.forename: S
authors.initials: S
authors.lastname: Nilsson
authors.forename: J E
authors.initials: JE
authors.lastname: Westlin
mesh_terms: D000368:Aged; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004369:Pentetic Acid / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D007205:Indium Radioisotopes; C071632:SDZ 215-811; D004369:Pentetic Acid; D015282:Octreotide